Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Thoracic Oncology - Volume 13, Issue 4, April 2018, Pages e49-e53

Jin MD, Hua-Jun MD, Zheng PhD, Jing MD, Bing Master, Tengfei PhD, Zhenfan MD, PhD, Yi-Long MD, Jin-Ji MD, PhD,